Clinical Research Lab, ICMR-National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India
Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia.
BMJ Open. 2021 Aug 9;11(8):e050844. doi: 10.1136/bmjopen-2021-050844.
Endometriosis is one of the common, gynaecological disorders associated with chronic pelvic pain and subfertility affecting ~10% of reproductive age women. The clinical presentation, etiopathogenesis of endometriosis subtypes and associated risk factors are largely unknown. Genome-Wide Association (GWA) Studies (GWAS) provide strong evidence for the role of genetic risk factors contributing to endometriosis. However, no studies have investigated the association of the GWAS-identified single-nucleotide polymorphism (SNPs) with endometriosis risk in the Indian population; therefore, one-sixth of the world's population is not represented in the global genome consortiums on endometriosis. The Endometriosis Clinical and Genetic Research in India (ECGRI) study aims to broaden our understanding of the clinical phenotypes and genetic risks associated with endometriosis.
ECGRI is a large-scale, multisite, case-control study of 2000 endometriosis cases and 2000 hospital controls to be recruited over 4 years at 15 collaborating study sites across India covering representative Indian population from east,north-east, north, central, west and southern geographical zones of India. We will use the World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project (WERF-EPHect) data collection instruments for capturing information on clinical, epidemiological, lifestyle, environmental and surgical factors. WERF-EPHect standard operating procedures will be followed for the collection, processing and storage of biological samples. The principal analyses will be for main outcome measures of the incidence of endometriosis, disease subtypes and disease severity determined from the clinical data. This will be followed by GWAS within and across ethnic groups.
The study is approved by the Institutional Ethics Committee of Indian Council of Medical Research-National Institute for Research in Reproductive Health and all participating study sites. The study is also approved by the Health Ministry Screening Committee of the Government of India. The results from this study will be actively disseminated through discussions with endometriosis patient groups, conference presentations and published manuscripts.
子宫内膜异位症是一种常见的妇科疾病,与慢性盆腔疼痛和不孕有关,影响约 10%的育龄妇女。子宫内膜异位症各亚型的临床表现、发病机制和相关危险因素在很大程度上尚不清楚。全基因组关联(GWA)研究(GWAS)为遗传风险因素在子宫内膜异位症中的作用提供了强有力的证据。然而,尚无研究探讨 GWAS 确定的单核苷酸多态性(SNPs)与印度人群子宫内膜异位症风险之间的关联;因此,全球子宫内膜异位症基因组联盟中没有代表世界六分之一的人口。印度子宫内膜异位症临床与遗传研究(ECGRI)旨在更深入地了解与子宫内膜异位症相关的临床表型和遗传风险。
ECGRI 是一项大型、多中心、病例对照研究,将在印度 15 个合作研究地点招募 2000 例子宫内膜异位症病例和 2000 例医院对照,研究时间为 4 年。该研究将覆盖印度东部、东北部、北部、中部、西部和南部地理区域的代表性印度人群。我们将使用世界子宫内膜异位症研究基金会子宫内膜异位症表型和生物样本库协调项目(WERF-EPHect)的数据收集工具,收集有关临床、流行病学、生活方式、环境和手术因素的信息。WERF-EPHect 标准操作规程将用于生物样本的收集、处理和存储。主要分析将针对主要结局指标进行,包括子宫内膜异位症的发病率、疾病亚型和疾病严重程度,这些指标将根据临床数据确定。随后将在不同种族群体内和跨种族群体进行 GWAS。
该研究已获得印度医学研究理事会国家生育与生殖健康研究所机构伦理委员会和所有参与研究地点的批准。该研究还获得了印度政府卫生部筛查委员会的批准。该研究的结果将通过与子宫内膜异位症患者群体的讨论、会议演讲和发表的论文积极传播。